September 2, 2002
Iressa Combined with Platinum Failed to Improve Survival AstraZeneca announced on August 19 that its anticancer agent Iressa (gefitinib), which was approved first in Japan, did not provide improvement in survival when added to the standard platinum-based chemotherapy in advanced...read more